Gene	Gene synonym	Ensembl	Gene description	Chromosome	Position	Protein class	Evidence	Antibody	Reliability (IH)	Reliability (Mouse Brain)	Reliability (IF)	Subcellular location	Prognostic p-value	RNA cancer category	RNA tissue category	RNA TS	RNA TS TPM	TPM max in non-specific	RNA cell line category	RNA CS	RNA CS TPM
DEFA6	DEF6, HD-6	ENSG00000164822	Defensin alpha 6	8	6924693-6926076	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA019462	Enhanced					Tissue enhanced	Group enriched	525	duodenum: 5743.0;small intestine: 10524.2	colon: 15.4	Group enriched	9	BEWO: 28.1;NB-4: 20.0;RPMI-8226: 25.8;SH-SY5Y: 26.0;U-2197: 10.6
DEFA5	DEF5, HD-5	ENSG00000164816	Defensin alpha 5	8	7055304-7056734	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015775, CAB069919	Enhanced				Colorectal cancer:9.44e-5 (favourable)	Tissue enhanced	Group enriched	480	duodenum: 10677.9;small intestine: 19102.0	appendix: 31.0	Group enriched	6	BEWO: 55.6;NB-4: 31.4;RPMI-8226: 35.9;SH-SY5Y: 42.9;U-2197: 16.2
INSL5		ENSG00000172410	Insulin like 5	1	66797741-66801256	Predicted secreted proteins	Evidence at protein level	HPA030100, CAB033849	Enhanced					Group enriched	Group enriched	228	colon: 77.7;rectum: 141.9	cerebral cortex: 0.4	Not detected		
AQP8		ENSG00000103375	Aquaporin 8	16	25215731-25228940	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046259	Enhanced					Group enriched	Group enriched	129	colon: 321.2;pancreas: 269.5;rectum: 166.5	smooth muscle: 1.9	Not detected		
C17orf78	FLJ39647	ENSG00000278505	Chromosome 17 open reading frame 78	17	37375986-37392708	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Group enriched	Group enriched	74	duodenum: 99.1;small intestine: 50.9	testis: 1.0	Not detected		
PRSS3	PRSS4, TRY3, TRY4	ENSG00000010438	Protease, serine 3	9	33750466-33799231	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA062452, HPA063471	Supported		Approved	Endoplasmic reticulum<br>Vesicles	Endometrial cancer:4.30e-4 (unfavourable)	Group enriched	Tissue enriched	64	pancreas: 6301.2	small intestine: 99.1	Cell line enriched	9	PC-3: 632.8
TEX43	C5orf48, FLJ27505, MGC163367, MGC163369, Tseg7	ENSG00000196900	Testis expressed 43	5	126631722-126636287	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	62	testis: 35.7	colon: 0.5	Not detected		
MEP1A	PPHA	ENSG00000112818	Meprin A subunit alpha	6	46793390-46839782	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB025163, HPA029416	Enhanced					Tissue enriched	Group enriched	42	colon: 117.8;duodenum: 282.2;rectum: 114.3;small intestine: 538.5	appendix: 6.2	Cell line enhanced		BEWO: 1.2;CACO-2: 2.4;RPMI-8226: 1.0
ISX	RAXLX	ENSG00000175329	Intestine specific homeobox	22	35066136-35087387	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060328	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Tissue enhanced	Group enriched	36	colon: 27.4;duodenum: 37.5;rectum: 28.2;small intestine: 29.7	smooth muscle: 0.8	Group enriched	12	CACO-2: 1.3;Hep G2: 3.1
KLK1	Klk6	ENSG00000167748	Kallikrein 1	19	50819148-50823787	Enzymes, Predicted secreted proteins	Evidence at protein level							Group enriched	Group enriched	36	pancreas: 1994.7;salivary gland: 2549.9	colon: 63.5	Cell line enriched	18	RPMI-8226: 26.9
TM4SF20	FLJ22800, TCCE518	ENSG00000168955	Transmembrane 4 L six family member 20	2	227362156-227381995	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051838, HPA063184, HPA065531	Uncertain		Supported	Plasma membrane<br>Focal adhesion sites		Group enriched	Group enriched	35	duodenum: 277.2;small intestine: 163.8	testis: 6.3	Cell line enhanced		A549: 2.5;RPMI-8226: 1.2
TFF1	BCEI, D21S21, HP1.A, HPS2, pNR-2, pS2	ENSG00000160182	Trefoil factor 1	21	42362282-42366594	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002170, HPA003425	Enhanced				Breast cancer:5.00e-4 (favourable), Endometrial cancer:5.67e-4 (favourable)	Group enriched	Tissue enriched	32	stomach: 6419.9	gallbladder: 203.1	Cell line enriched	49	MCF7: 8447.1
CA1	Car1	ENSG00000133742	Carbonic anhydrase 1	8	85327608-85379014	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006558, CAB025790	Enhanced					Group enriched	Group enriched	30	bone marrow: 1216.6;colon: 1022.8;rectum: 2316.0	smooth muscle: 49.9	Cell line enriched	1560	HEL: 1145.7
TBX10	TBX13, TBX7	ENSG00000167800	T-box 10	11	67631303-67639560	Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA047881	Uncertain					Group enriched	Group enriched	27	colon: 8.8;duodenum: 5.8;rectum: 8.6;small intestine: 10.6	appendix: 0.3	Cell line enhanced		NTERA-2: 5.3;RPMI-8226: 2.5;SK-BR-3: 9.3;U-2 OS: 2.7
BTNL3	BTN9.1, BTNLR	ENSG00000168903	Butyrophilin like 3	5	180988845-181006727	Predicted membrane proteins	Evidence at transcript level							Group enriched	Group enriched	25	colon: 24.5;duodenum: 115.1;rectum: 26.3;small intestine: 89.1	gallbladder: 2.5	Not detected		
MUC12	MUC11	ENSG00000205277	Mucin 12, cell surface associated	7	100969623-101018949	Predicted membrane proteins	Evidence at protein level	HPA023835	Enhanced					Tissue enriched	Group enriched	24	colon: 49.6;rectum: 74.4	appendix: 2.5	Not detected		
TMIGD1	TMIGD, UNQ9372	ENSG00000182271	Transmembrane and immunoglobulin domain containing 1	17	30316333-30334059	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA021946			Approved	Mitochondria		Tissue enhanced	Group enriched	23	colon: 81.8;rectum: 109.8;small intestine: 162.9	kidney: 5.1	Not detected		
APOBEC1	APOBEC-1, BEDP, CDAR1, HEPR	ENSG00000111701	Apolipoprotein B mRNA editing enzyme catalytic subunit 1	12	7649400-7665903	Enzymes, Predicted intracellular proteins	Evidence at protein level							Group enriched	Group enriched	21	duodenum: 31.9;small intestine: 31.0	stomach: 1.5	Cell line enriched	17	CAPAN-2: 2.4
C5orf52		ENSG00000187658	Chromosome 5 open reading frame 52	5	157671553-157680143	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	21	testis: 38.7	colon: 1.8	Not detected		
MS4A12	FLJ20217, Ms4a10	ENSG00000071203	Membrane spanning 4-domains A12	11	60492778-60507430	Predicted membrane proteins	Evidence at protein level	HPA057657	Enhanced					Tissue enriched	Group enriched	19	colon: 235.5;rectum: 280.6	appendix: 13.2	Cell line enhanced		RH-30: 1.1
IGF2	C11orf43, FLJ44734, IGF-II	ENSG00000167244	Insulin like growth factor 2	11	2129112-2141238	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007556, HPA007993	Enhanced		Approved	Nucleoplasm<br>Vesicles	Liver cancer:7.12e-4 (favourable)	Group enriched	Tissue enriched	18	placenta: 3962.9	fallopian tube: 217.6	Cell line enhanced		CACO-2: 711.5;Hep G2: 406.1;LHCN-M2: 277.7;RH-30: 396.9;SH-SY5Y: 525.9
MYADML2	LOC255275	ENSG00000185105	Myeloid associated differentiation marker like 2	17	81939645-81947233	Predicted membrane proteins	Evidence at transcript level	HPA041856, HPA048476	Uncertain					Tissue enhanced	Tissue enriched	17	skeletal muscle: 28.8	heart muscle: 1.6	Cell line enriched	8	SCLC-21H: 3.6
NOX1	GP91-2, MOX1, NOH-1, NOH1	ENSG00000007952	NADPH oxidase 1	X	100843324-100874345	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Colorectal cancer:9.71e-4 (favourable)	Tissue enriched	Group enriched	17	colon: 58.7;rectum: 79.9	appendix: 3.9	Cell line enriched	19	CACO-2: 25.5
SPACA3	ALLP17, CT54, LYC3, LYZL3, SLLP1	ENSG00000141316	Sperm acrosome associated 3	17	32970376-32997877	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023633	Enhanced					Tissue enhanced	Tissue enriched	17	testis: 77.5	pancreas: 4.5	Cell line enriched	17	U-266/70: 72.1
DUSP27		ENSG00000198842	Dual specificity phosphatase 27 (putative)	1	167094045-167129165	Predicted intracellular proteins	Evidence at protein level	HPA012608, HPA012912	Uncertain		Approved	Nucleoplasm		Group enriched	Group enriched	15	heart muscle: 41.9;skeletal muscle: 39.7	placenta,prostate: 2.6	Cell line enriched	11	RH-30: 13.7
GUCA2A	GUCA2, STARA	ENSG00000197273	Guanylate cyclase activator 2A	1	42162691-42164718	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA018215	Enhanced					Group enriched	Group enriched	15	colon: 768.8;rectum: 859.2;small intestine: 1127.0	duodenum: 61.5	Cell line enhanced		BEWO: 11.8;CACO-2: 8.2;NB-4: 2.0;U-2197: 2.5
CHST5	FLJ22167, I-GLCNAC-6-ST	ENSG00000135702	Carbohydrate sulfotransferase 5	16	75528535-75535247	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043804	Enhanced					Group enriched	Group enriched	14	colon: 45.6;duodenum: 85.9;rectum: 59.7;small intestine: 83.5	stomach: 4.8	Mixed		
GUCY2C	GUC2C, STAR	ENSG00000070019	Guanylate cyclase 2C	12	14612632-14696585	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037655, HPA073759	Uncertain		Uncertain	Vesicles	Liver cancer:1.37e-5 (unfavourable)	Group enriched	Group enriched	13	colon: 37.0;duodenum: 68.7;rectum: 45.4;small intestine: 73.2	appendix: 4.4	Cell line enhanced		AN3-CA: 1.2;CAPAN-2: 1.4;SiHa: 1.6
MYO1A	DFNA48, MYHL	ENSG00000166866	Myosin IA	12	57028517-57051198	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053490	Enhanced					Group enriched	Group enriched	13	colon: 67.8;duodenum: 333.2;rectum: 71.8;small intestine: 338.4	stomach: 16.1	Cell line enhanced		BEWO: 1.9;CACO-2: 6.6;Hep G2: 3.7
NAT2	AAC2	ENSG00000156006	N-acetyltransferase 2	8	18391245-18401218	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043704	Uncertain				Colorectal cancer:4.61e-5 (favourable)	Tissue enhanced	Group enriched	13	colon: 14.4;duodenum: 32.7;liver: 62.4;rectum: 14.0;small intestine: 27.1	smooth muscle: 2.3	Cell line enhanced		RT4: 1.2;SCLC-21H: 2.5;SK-BR-3: 1.0
NXPE1	FAM55A, MGC34290	ENSG00000095110	Neurexophilin and PC-esterase domain family member 1	11	114521715-114559895	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049133	Enhanced					Tissue enriched	Group enriched	13	colon: 111.8;rectum: 165.9	appendix: 10.5	Not detected		
CDHR2	FLJ20124, FLJ20383, PC-LKC, PCDH24, PCLKC	ENSG00000074276	Cadherin related family member 2	5	176542511-176595974	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA012569, HPA017053	Enhanced				Renal cancer:9.29e-4 (favourable)	Group enriched	Group enriched	12	duodenum: 276.5;small intestine: 260.3	colon: 22.6	Cell line enriched	12	Hep G2: 15.0
FABP2	I-FABP	ENSG00000145384	Fatty acid binding protein 2	4	119317250-119322390	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034607, CAB047325, CAB047326	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Cytosol		Group enriched	Group enriched	12	duodenum: 261.4;small intestine: 554.5	rectum: 33.8	Not detected		
LYPD8		ENSG00000259823	LY6/PLAUR domain containing 8	1	248718649-248755739	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	12	colon: 216.6;rectum: 141.8	appendix: 14.4	Not detected		
XPNPEP2		ENSG00000122121	X-prolyl aminopeptidase 2	X	129738974-129769538	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA000339, CAB025136, CAB025269	Enhanced					Group enriched	Group enriched	12	duodenum: 128.1;kidney: 175.9;small intestine: 231.5	liver: 14.3	Cell line enhanced		ASC diff: 6.9;ASC TERT1: 36.6;HSkMC: 19.4
SLC18A1	CGAT, VAT1, VMAT1	ENSG00000036565	Solute carrier family 18 member A1	8	20144855-20183206	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006877, HPA063797	Enhanced					Tissue enhanced	Tissue enriched	11	adrenal gland: 32.6	rectum: 3.0	Cell line enriched	9	SH-SY5Y: 70.0
CHP2		ENSG00000166869	Calcineurin like EF-hand protein 2	16	23754627-23758951	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB072806	Approved					Tissue enhanced	Group enriched	10	colon: 119.1;duodenum: 252.0;rectum: 127.6;skin: 143.8;small intestine: 227.3	cervix, uterine: 17.1	Cell line enhanced		hTERT-HME1: 4.5;NB-4: 4.6
HHLA2	B7-H5, B7H7, B7y	ENSG00000114455	HERV-H LTR-associating 2	3	108296490-108378285	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055478	Enhanced					Group enriched	Group enriched	10	colon: 87.7;duodenum: 87.1;gallbladder: 46.0;rectum: 90.5;small intestine: 143.9	stomach: 9.2	Cell line enhanced		HDLM-2: 3.7;Karpas-707: 2.0
NR1I2	BXR, ONR1, PAR2, PXR, SXR	ENSG00000144852	Nuclear receptor subfamily 1 group I member 2	3	119780484-119818485	FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029309, HPA055121, HPA073926			Enhanced	Nucleoplasm		Group enriched	Group enriched	10	colon: 10.3;duodenum: 27.2;gallbladder: 6.4;liver: 20.0;rectum: 10.7;small intestine: 30.0	stomach: 1.7	Group enriched	7	Hep G2: 9.8;RH-30: 3.3
ATOH1	bHLHa14, HATH1, MATH-1, Math1	ENSG00000172238	Atonal bHLH transcription factor 1	4	93828753-93830964	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Colorectal cancer:3.26e-5 (favourable)	Tissue enhanced	Group enriched	9	colon: 17.6;duodenum: 11.1;rectum: 19.7;small intestine: 22.4	appendix: 1.9	Not detected		
CDHR5	FLJ20219, MU-PCDH, MUCDHL, MUPCDH	ENSG00000099834	Cadherin related family member 5	11	616565-626078	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009081, HPA009173, CAB025004	Enhanced					Group enriched	Group enriched	9	colon: 41.7;duodenum: 82.7;kidney: 23.6;liver: 21.0;rectum: 54.3;small intestine: 64.3	gallbladder: 5.3	Cell line enhanced		CACO-2: 2.1
CDX1		ENSG00000113722	Caudal type homeobox 1	5	150166795-150184558	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055196	Enhanced					Tissue enhanced	Group enriched	9	colon: 129.9;duodenum: 64.5;rectum: 134.7;small intestine: 104.9	appendix: 12.1	Cell line enhanced		BJ hTERT+: 5.4;SH-SY5Y: 1.3
LRRC19	FLJ21302	ENSG00000184434	Leucine rich repeat containing 19	9	26993136-27005693	Predicted membrane proteins	Evidence at protein level						Renal cancer:7.08e-8 (favourable)	Group enriched	Group enriched	9	colon: 35.9;duodenum: 23.7;gallbladder: 9.4;kidney: 45.1;rectum: 35.3;small intestine: 34.7	appendix: 3.5	Not detected		
NXPE4	C11orf33, FAM55D, FLJ20127	ENSG00000137634	Neurexophilin and PC-esterase domain family member 4	11	114570591-114595762	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042801	Approved					Tissue enriched	Group enriched	9	colon: 139.6;rectum: 158.4;salivary gland: 38.2	appendix: 11.9	Not detected		
REG1A	PSP, PSPS, PSPS1, PTP, REG	ENSG00000115386	Regenerating family member 1 alpha	2	79120362-79123419	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025138, HPA045549, HPA045579	Enhanced					Group enriched	Group enriched	9	duodenum: 7122.5;pancreas: 10867.0;small intestine: 4615.5	stomach: 847.5	Cell line enhanced		BEWO: 11.1;EFO-21: 16.2;HDLM-2: 13.2;RPMI-8226: 20.2;SH-SY5Y: 12.6;U-2 OS: 28.7
REG4	GISP, REG-IV, RELP	ENSG00000134193	Regenerating family member 4	1	119794018-119811660	Predicted secreted proteins	Evidence at protein level	CAB025867, HPA046555	Enhanced					Group enriched	Group enriched	9	colon: 215.7;duodenum: 239.5;rectum: 299.4;small intestine: 664.5	appendix: 39.6	Group enriched	24	PC-3: 85.3;RT4: 20.5
TMEM236	bA162I21.2, bA16O1.2, FAM23A, FAM23B	ENSG00000148483	Transmembrane protein 236	10	17752252-17800868	Predicted membrane proteins	Evidence at protein level	HPA045096	Enhanced					Tissue enhanced	Group enriched	9	colon: 14.4;duodenum: 22.1;rectum: 15.5;small intestine: 37.7	appendix: 2.3	Cell line enriched	9	MOLT-4: 8.4
CDH17	cadherin, HPT-1	ENSG00000079112	Cadherin 17	8	94127171-94217303	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023614, HPA023616, CAB025143, HPA026556	Enhanced		Supported	Cell Junctions		Group enriched	Group enriched	8	colon: 256.9;duodenum: 314.3;rectum: 267.3;small intestine: 294.3	appendix: 37.5	Group enriched	6	CACO-2: 81.5;U-266/70: 121.0
CLCA1	CaCC, CLCRG1	ENSG00000016490	Chloride channel accessory 1	1	86468368-86500289	Predicted secreted proteins, Transporters	Evidence at protein level	HPA052787, HPA059301	Enhanced				Colorectal cancer:2.98e-4 (favourable)	Group enriched	Group enriched	8	colon: 699.6;duodenum: 882.2;rectum: 1126.3;small intestine: 1522.4	appendix: 133.7	Cell line enhanced		BEWO: 1.9;NB-4: 1.5;RPMI-8226: 1.8;SH-SY5Y: 1.9;U-2197: 1.3
CLRN3	MGC32871, TMEM12, USH3AL1	ENSG00000180745	Clarin 3	10	127877841-127892947	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014482	Approved				Stomach cancer:8.98e-4 (favourable)	Group enriched	Group enriched	8	colon: 69.9;duodenum: 73.3;gallbladder: 23.6;kidney: 44.3;liver: 40.4;rectum: 76.3;small intestine: 97.5	appendix: 7.2	Cell line enriched	6	CACO-2: 1.9
GAL3ST2	GP3ST	ENSG00000154252	Galactose-3-O-sulfotransferase 2	2	241776825-241804208	Predicted secreted proteins	Evidence at protein level	HPA071809	Enhanced					Group enriched	Group enriched	8	colon: 9.3;rectum: 4.0	appendix,fallopian tube: 0.8	Cell line enhanced		Hep G2: 1.4
GPA33	A33	ENSG00000143167	Glycoprotein A33	1	167052836-167166479	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018858, CAB025943	Enhanced					Tissue enriched	Group enriched	8	colon: 183.6;duodenum: 130.8;rectum: 188.7;small intestine: 131.3	appendix: 19.0	Cell line enhanced		NTERA-2: 1.0
MUC17		ENSG00000169876	Mucin 17, cell surface associated	7	101020072-101058745	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA031634	Enhanced					Group enriched	Group enriched	8	duodenum: 21.8;small intestine: 42.5	rectum: 3.8	Not detected		
SOX1		ENSG00000182968	SRY-box 1	13	112067647-112070488	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Group enriched	Group enriched	8	cerebral cortex: 3.6;testis: 1.5	skin: 0.3	Group enriched	6	AF22: 44.0;SCLC-21H: 10.1
CEACAM7	CEA, CGM2	ENSG00000007306	Carcinoembryonic antigen related cell adhesion molecule 7	19	41673307-41706976	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069621	Supported					Tissue enhanced	Group enriched	7	colon: 583.2;rectum: 691.9	appendix: 91.6	Not detected		
EPS8L3	FLJ21522, MGC16817	ENSG00000198758	EPS8 like 3	1	109750080-109764027	Predicted intracellular proteins	Evidence at protein level	HPA030998	Approved		Approved	Vesicles	Renal cancer:2.52e-5 (unfavourable), Liver cancer:4.13e-5 (unfavourable), Urothelial cancer:1.82e-4 (favourable)	Group enriched	Group enriched	7	colon: 75.0;duodenum: 152.1;gallbladder: 59.8;rectum: 86.1;small intestine: 167.1;stomach: 53.4	appendix: 15.1	Group enriched	12	CACO-2: 13.3;CAPAN-2: 13.3;EFO-21: 5.8;Hep G2: 25.0
FABP1	L-FABP	ENSG00000163586	Fatty acid binding protein 1	2	88122982-88128116	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002305, HPA028275	Enhanced		Approved	Nucleoplasm<br>Cytosol		Group enriched	Group enriched	7	colon: 4552.0;duodenum: 4123.5;liver: 5672.8;rectum: 3081.5;small intestine: 4506.9	kidney: 602.3	Group enriched	6	CACO-2: 84.1;Hep G2: 221.3
PDX1	IDX-1, IPF1, MODY4, PDX-1, STF-1	ENSG00000139515	Pancreatic and duodenal homeobox 1	13	27920020-27926231	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025873, HPA059146	Enhanced		Supported	Nucleoplasm		Group enriched	Tissue enriched	7	duodenum: 43.6	stomach: 6.2	Group enriched	6	AN3-CA: 1.2;CACO-2: 1.0;CAPAN-2: 1.2;HDLM-2: 3.9;HEK 293: 2.2;HeLa: 4.1
PHGR1		ENSG00000233041	Proline, histidine and glycine rich 1	15	40351033-40356434	Predicted intracellular proteins	Evidence at protein level	HPA068787	Enhanced		Approved	Vesicles	Breast cancer:2.05e-4 (favourable)	Group enriched	Group enriched	7	colon: 1448.4;duodenum: 892.1;rectum: 399.5;small intestine: 1777.5	stomach: 166.8	Cell line enhanced		BEWO: 12.3;HaCaT: 16.0;SCLC-21H: 72.5
PPP1R14D	CPI17-like, FLJ20251, GBPI-1, MGC119014, MGC119016	ENSG00000166143	Protein phosphatase 1 regulatory inhibitor subunit 14D	15	40815445-40828709	Predicted intracellular proteins	Evidence at protein level	HPA041846	Uncertain				Renal cancer:3.07e-4 (unfavourable)	Tissue enhanced	Group enriched	7	colon: 105.5;duodenum: 111.1;gallbladder: 24.2;rectum: 100.0;small intestine: 89.8	appendix: 12.4	Cell line enhanced		RPMI-8226: 2.1;RT4: 1.5;U-266/84: 1.4
VIL1	D2S1471, VIL	ENSG00000127831	Villin 1	2	218419092-218453295	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002452, HPA006884, HPA006885	Enhanced		Enhanced	Plasma membrane		Tissue enhanced	Group enriched	7	colon: 173.7;duodenum: 398.5;rectum: 199.6;small intestine: 480.0	gallbladder: 44.7	Group enriched	91	CACO-2: 628.4;Hep G2: 245.1
ACSL6	ACS2, FACL6, KIAA0837, LACS2, LACS5	ENSG00000164398	Acyl-CoA synthetase long-chain family member 6	5	131949973-132012243	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040470	Enhanced					Group enriched	Group enriched	6	bone marrow: 18.0;cerebral cortex: 61.9;parathyroid gland: 22.5;seminal vesicle: 29.0;testis: 51.4	adrenal gland: 6.4	Group enriched	6	SCLC-21H: 13.0;U-937: 5.2
BTNL8	BTN9.2, FLJ21458	ENSG00000113303	Butyrophilin like 8	5	180899077-180950906	Predicted membrane proteins	Evidence at protein level	HPA039738	Approved					Group enriched	Group enriched	6	colon: 26.1;duodenum: 117.4;rectum: 27.7;small intestine: 94.2	gallbladder: 10.4	Cell line enriched	26	CACO-2: 31.4
CASP5	ICE(rel)III	ENSG00000137757	Caspase 5	11	104994235-105023168	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040937	Uncertain					Group enriched	Group enriched	6	appendix: 20.2;colon: 15.9;duodenum: 10.1;rectum: 14.5;small intestine: 18.9	smooth muscle: 2.7	Cell line enriched	8	HHSteC: 3.1
CDX2	CDX3	ENSG00000165556	Caudal type homeobox 2	13	27962137-27971139	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002221, HPA045669, HPA049580	Enhanced		Supported	Nucleoplasm		Tissue enriched	Group enriched	6	colon: 30.8;duodenum: 22.3;rectum: 24.9;small intestine: 30.2	appendix: 4.7	Cell line enhanced		CACO-2: 9.4;CAPAN-2: 3.3;HEK 293: 5.6
EFNA2	ELF-1, EPLG6, LERK6	ENSG00000099617	Ephrin A2	19	1286154-1300237	Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005178, HPA067567	Uncertain		Approved	Mitochondria<br>Cytosol		Tissue enhanced	Group enriched	6	colon: 7.0;duodenum: 7.9;small intestine: 10.6	rectum: 1.5	Cell line enhanced		Hep G2: 6.6;NTERA-2: 5.4;REH: 6.8;SH-SY5Y: 17.8;U-2 OS: 5.8
EREG	ER	ENSG00000124882	Epiregulin	4	74365143-74388751	Predicted membrane proteins	Evidence at protein level	HPA054373			Approved	Vesicles	Cervical cancer:1.67e-7 (unfavourable), Lung cancer:1.45e-5 (unfavourable), Pancreatic cancer:6.57e-5 (unfavourable)	Tissue enhanced	Tissue enriched	6	bone marrow: 82.3	appendix: 14.4	Cell line enhanced		BJ hTERT+: 218.4;U-2197: 168.6;U-87 MG: 300.8
GJB4	CX30.3	ENSG00000189433	Gap junction protein beta 4	1	34759741-34763724	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA055112			Supported	Cell Junctions	Pancreatic cancer:3.24e-5 (unfavourable), Cervical cancer:5.48e-4 (favourable)	Group enriched	Tissue enriched	6	skin: 27.7	epididymis: 4.6	Cell line enhanced		A-431: 4.0;HaCaT: 5.8;HBEC3-KT: 3.1;hTCEpi: 2.0;RPTEC TERT1: 1.9;RT4: 2.4
HNF4A	HNF4, MODY, MODY1, NR2A1, TCF14	ENSG00000101076	Hepatocyte nuclear factor 4 alpha	20	44355700-44434596	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004712, CAB019417	Enhanced		Supported	Nucleoplasm		Tissue enhanced	Group enriched	6	colon: 58.0;duodenum: 103.0;kidney: 44.7;liver: 51.0;rectum: 47.8;small intestine: 90.9;stomach: 21.9	gallbladder: 9.2	Group enriched	8	CACO-2: 126.0;Hep G2: 77.0
IHH	BDA1, HHG2	ENSG00000163501	Indian hedgehog	2	219054420-219060467	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:3.67e-6 (favourable)	Tissue enhanced	Group enriched	6	cervix, uterine: 8.9;colon: 21.0;duodenum: 14.9;endometrium: 31.4;rectum: 16.7;small intestine: 16.5;stomach: 15.3	prostate: 3.2	Cell line enriched	11	CACO-2: 16.8
MISP	C19orf21, Caprice, DKFZp686H18209, MISP1	ENSG00000099812	Mitotic spindle positioning	19	751126-764318	Predicted intracellular proteins	Evidence at protein level	HPA049511, HPA062232	Enhanced		Enhanced	Plasma membrane<br>Focal adhesion sites		Tissue enhanced	Group enriched	6	colon: 94.7;duodenum: 173.3;rectum: 52.6;small intestine: 217.1	stomach: 21.6	Cell line enhanced		A549: 110.0;HaCaT: 79.4;hTCEpi: 59.7;SK-BR-3: 101.1
MOGAT3	DC7, DGAT2L2, MGAT3	ENSG00000106384	Monoacylglycerol O-acyltransferase 3	7	101195007-101201021	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA011940	Uncertain		Approved	Centrosome		Tissue enhanced	Group enriched	6	colon: 11.3;duodenum: 30.4;rectum: 11.9;small intestine: 33.6	liver: 3.4	Cell line enhanced		CACO-2: 2.9;Hep G2: 8.1
MUC13	DRCC1	ENSG00000173702	Mucin 13, cell surface associated	3	124905442-124953819	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045163	Enhanced				Renal cancer:9.73e-5 (unfavourable)	Tissue enhanced	Group enriched	6	colon: 301.8;duodenum: 614.7;rectum: 330.1;small intestine: 555.7	appendix: 79.5	Cell line enhanced		A549: 6.6;CACO-2: 5.3;CAPAN-2: 11.9;Karpas-707: 5.6
NEU4		ENSG00000204099	Neuraminidase 4	2	241808825-241817413	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037394, HPA037395	Uncertain					Group enriched	Group enriched	6	bone marrow: 2.4;cerebral cortex: 6.3;colon: 8.3;duodenum: 5.6;liver: 4.1;rectum: 3.7;small intestine: 5.3	fallopian tube,gallbladder: 0.7	Group enriched	20	Hep G2: 26.3;HMC-1: 45.5
PRAP1	UPA	ENSG00000165828	Proline rich acidic protein 1	10	133347146-133352683	Predicted secreted proteins	Evidence at protein level	HPA038713, HPA052451	Supported		Uncertain	Nucleoplasm<br>Vesicles<br>Plasma membrane		Group enriched	Group enriched	6	duodenum: 928.6;liver: 297.4;small intestine: 1097.7	kidney: 125.6	Group enriched	5	CACO-2: 18.2;Hep G2: 64.2
SPINK4	MGC133107, PEC-60	ENSG00000122711	Serine peptidase inhibitor, Kazal type 4	9	33218365-33248567	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007286	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Colorectal cancer:8.85e-5 (favourable)	Group enriched	Group enriched	6	colon: 631.8;duodenum: 266.4;rectum: 1071.3;small intestine: 734.5	appendix: 107.1	Cell line enriched	8	HMC-1: 152.9
TRIM31	C6orf13, HCG1, HCGI, RNF	ENSG00000204616	Tripartite motif containing 31	6	30102897-30113106	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046400	Uncertain					Group enriched	Group enriched	6	colon: 10.0;small intestine: 2.3;stomach: 2.1;urinary bladder: 2.7	duodenum: 0.7	Cell line enriched	527	RT4: 232.7
URAD	PRHOXNB	ENSG00000183463	Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase	13	27977714-27988654	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA038972	Uncertain					Tissue enriched	Group enriched	6	colon: 12.6;duodenum: 8.3;small intestine: 17.9	appendix: 2.3	Group enriched	12	BEWO: 2.6;CACO-2: 2.1
ZG16	hZG16, JCLN, JCLN1, ZG16A	ENSG00000174992	Zymogen granule protein 16	16	29778240-29782973	Predicted secreted proteins	Evidence at protein level	HPA052066, HPA052512	Enhanced					Tissue enriched	Group enriched	6	colon: 363.4;rectum: 502.4;small intestine: 121.4	duodenum: 57.7	Cell line enhanced		SK-BR-3: 1.7
AKR7A3		ENSG00000162482	Aldo-keto reductase family 7 member A3	1	19282558-19289250	Predicted intracellular proteins	Evidence at protein level	HPA064638			Approved	Cytosol	Renal cancer:8.80e-7 (favourable)	Group enriched	Group enriched	5	duodenum: 170.4;gallbladder: 38.7;kidney: 49.0;liver: 44.8;small intestine: 106.8;stomach: 70.3	colon: 15.9	Cell line enhanced		SK-BR-3: 12.6
ANXA13	ANX13	ENSG00000104537	Annexin A13	8	123680794-123737407	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018535, HPA019569, HPA019650, CAB025135	Enhanced		Supported	Plasma membrane		Group enriched	Group enriched	5	duodenum: 296.6;fallopian tube: 92.7;gallbladder: 227.6;small intestine: 235.6	rectum: 39.2	Group enriched	16	A549: 25.3;HDLM-2: 13.7
CDHR1	CORD15, KIAA1775, PCDH21, RP65	ENSG00000148600	Cadherin related family member 1	10	84194635-84219621	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036819	Supported					Tissue enhanced	Group enriched	5	rectum: 57.9;skin: 252.1	colon: 29.2	Cell line enhanced		HAP1: 10.5;HEK 293: 4.8;HEL: 5.7;RPTEC TERT1: 12.5
CLC	Gal-10, LGALS10, MGC149659	ENSG00000105205	Charcot-Leyden crystal galectin	19	39731250-39738028	Predicted intracellular proteins	Evidence at protein level	HPA041751	Enhanced					Tissue enhanced	Tissue enriched	5	bone marrow: 285.9	urinary bladder: 55.3	Cell line enriched	14	HMC-1: 6580.2
MGAM2		ENSG00000257743	Maltase-glucoamylase 2 (putative)	7	142111749-142222324	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA055697	Enhanced		Approved	Vesicles<br>Cytosol		Group enriched	Group enriched	5	duodenum: 11.8;small intestine: 10.4	salivary gland: 2.1	Cell line enriched	7	RH-30: 1.1
NOS2	HEP-NOS, iNOS, NOS, NOS2A	ENSG00000007171	Nitric oxide synthase 2	17	27756766-27800499	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002014	Approved					Tissue enhanced	Group enriched	5	appendix: 18.9;colon: 7.0;duodenum: 12.3;rectum: 9.8;small intestine: 24.1;urinary bladder: 6.5	smooth muscle: 2.5	Group enriched	8	CACO-2: 13.0;SCLC-21H: 14.7
PF4	CXCL4, SCYB4	ENSG00000163737	Platelet factor 4	4	73981077-73982124	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026008, HPA052485	Enhanced					Tissue enhanced	Group enriched	5	bone marrow: 53.7;spleen: 13.4	placenta: 6.5	Cell line enriched	13	HEL: 37.2
SATB2	FLJ21474, KIAA1034	ENSG00000119042	SATB homeobox 2	2	199269500-199471266	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001042, CAB023669, HPA029543, CAB062562, CAB067751, CAB068229, CAB068230, CAB068231	Enhanced		Supported	Nucleoplasm	Renal cancer:5.37e-8 (favourable)	Tissue enhanced	Group enriched	5	cerebral cortex: 22.7;colon: 34.1;rectum: 43.2	small intestine: 6.3	Mixed		
SULT1B1	ST1B2	ENSG00000173597	Sulfotransferase family 1B member 1	4	69721162-69787961	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002107	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus		Group enriched	Group enriched	5	colon: 68.9;duodenum: 99.0;rectum: 67.1;small intestine: 103.7;stomach: 41.6	appendix: 13.8	Group enriched	6	HUVEC TERT2: 92.0;TIME: 29.6;U-2197: 29.2
VIP		ENSG00000146469	Vasoactive intestinal peptide	6	152750798-152759765	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017324, CAB018649, HPA072701	Supported		Approved	Endoplasmic reticulum		Group enriched	Group enriched	5	appendix: 209.4;colon: 71.4;rectum: 68.3;small intestine: 52.7;smooth muscle: 58.1	duodenum: 16.8	Cell line enhanced		SH-SY5Y: 2.8;TIME: 1.6
AGMAT	FLJ23384	ENSG00000116771	Agmatinase	1	15572353-15585110	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026443, HPA028321	Enhanced				Renal cancer:5.13e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 158.9	liver: 36.6	Cell line enhanced		CACO-2: 35.2;Hep G2: 70.8
AIFM3	AIFL, FLJ30473	ENSG00000183773	Apoptosis inducing factor, mitochondria associated 3	22	20965108-20981360	Predicted intracellular proteins	Evidence at protein level	HPA001271			Enhanced	Mitochondria	Urothelial cancer:7.13e-5 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 18.5;colon: 18.7	rectum: 9.0	Cell line enhanced		Hep G2: 5.1;HMC-1: 9.5;T-47d: 5.0;THP-1: 5.1
ANKS4B	FLJ38819, HARP	ENSG00000175311	Ankyrin repeat and sterile alpha motif domain containing 4B	16	21233665-21253845	Predicted intracellular proteins	Evidence at protein level	HPA043523	Approved		Approved	Nucleoplasm<br>Cytosol		Group enriched	Tissue enhanced		duodenum: 9.0;rectum: 7.8;small intestine: 12.9	colon: 6.8	Group enriched	10	CACO-2: 1.1;HDLM-2: 3.2;Hep G2: 5.5
ANO9	PIG5, TMEM16J, TP53I5	ENSG00000185101	Anoctamin 9	11	417933-442011	Predicted membrane proteins, Transporters	Evidence at protein level	HPA039948, HPA040112	Approved		Uncertain	Golgi apparatus	Urothelial cancer:8.81e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 31.6;small intestine: 30.9	skin: 21.6	Cell line enhanced		BEWO: 8.6;CAPAN-2: 24.1;HaCaT: 14.1;RPMI-8226: 13.6
AOC1	ABP1, DAO	ENSG00000002726	Amine oxidase, copper containing 1	7	150824627-150861504	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA031032, HPA031033	Approved				Prostate cancer:1.71e-4 (favourable)	Group enriched	Tissue enhanced		placenta: 716.9;small intestine: 247.6	duodenum: 183.2	Cell line enhanced		CAPAN-2: 17.4;HaCaT: 5.4;THP-1: 17.8
ARL14	ARF7, FLJ22595	ENSG00000179674	ADP ribosylation factor like GTPase 14	3	160677159-160678452	Predicted intracellular proteins	Evidence at protein level						Lung cancer:2.64e-5 (unfavourable), Pancreatic cancer:6.71e-4 (unfavourable)	Group enriched	Tissue enhanced		gallbladder: 209.1;stomach: 70.2	duodenum: 50.9	Group enriched	5	A-431: 8.4;CAPAN-2: 31.7;HaCaT: 7.9;RT4: 14.0
ASCL2	ASH2, bHLHa45, HASH2	ENSG00000183734	Achaete-scute family bHLH transcription factor 2	11	2268495-2270952	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Pancreatic cancer:4.73e-4 (favourable), Cervical cancer:5.11e-4 (favourable)	Group enriched	Mixed			placenta: 6.4	Group enriched	6	BEWO: 19.9;NB-4: 4.0;SCLC-21H: 19.8
ATP10B	ATPVB, FLJ21477, KIAA0715	ENSG00000118322	ATPase phospholipid transporting 10B (putative)	5	160563120-160852214	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034574	Uncertain					Group enriched	Tissue enhanced		colon: 36.0;rectum: 40.3	gallbladder: 21.4	Cell line enriched	23	WM-115: 13.6
B3GNT6	B3Gn-T6	ENSG00000198488	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6	11	77034398-77041973	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA012158, HPA039805	Enhanced	Approved			Colorectal cancer:2.31e-4 (favourable)	Group enriched	Tissue enhanced		colon: 21.7;rectum: 18.2;stomach: 23.5	small intestine: 7.9	Not detected		
BCL2L14	BCL-G, BCLG	ENSG00000121380	BCL2 like 14	12	12049844-12211084	Predicted intracellular proteins	Evidence at protein level	HPA040665	Enhanced		Uncertain	Cytosol		Tissue enhanced	Tissue enhanced		rectum: 16.9;testis: 24.1	small intestine: 14.2	Group enriched	5	CAPAN-2: 1.8;NTERA-2: 1.6;RT4: 1.5
BCL2L15	Bfk, C1orf178, FLJ22588	ENSG00000188761	BCL2 like 15	1	113878168-113887547	Predicted intracellular proteins	Evidence at protein level	HPA029732, HPA029733	Enhanced				Endometrial cancer:5.63e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 47.4;duodenum: 66.5;rectum: 52.2;small intestine: 64.3	stomach: 24.0	Cell line enhanced		CAPAN-2: 22.4;EFO-21: 8.1;RPTEC TERT1: 5.6
BEST2	FLJ20132, VMD2L1	ENSG00000039987	Bestrophin 2	19	12751702-12758458	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA046229	Approved					Tissue enhanced	Tissue enhanced		colon: 15.4;rectum: 14.8	tonsil: 4.5	Mixed		
C6orf222	DKFZp779B1540	ENSG00000189325	Chromosome 6 open reading frame 222	6	36315757-36336885	Predicted intracellular proteins	Evidence at protein level	HPA038407, HPA058189	Uncertain					Group enriched	Tissue enhanced		duodenum: 24.7;small intestine: 26.4	rectum: 6.2	Not detected		
CA7		ENSG00000168748	Carbonic anhydrase 7	16	66844379-66854153	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047237	Uncertain					Tissue enhanced	Tissue enhanced		colon: 54.6;rectum: 49.8	small intestine: 10.7	Cell line enhanced		REH: 1.0;SCLC-21H: 1.0;THP-1: 1.2
CCL24	Ckb-6, eotaxin-2, MPIF-2, MPIF2, SCYA24	ENSG00000106178	C-C motif chemokine ligand 24	7	75811665-75823356	Predicted secreted proteins	Evidence at protein level						Colorectal cancer:5.41e-4 (favourable)	Tissue enhanced	Tissue enhanced		rectum: 111.7;small intestine: 96.2	urinary bladder: 51.4	Cell line enhanced		CAPAN-2: 4.8;RH-30: 2.0;U-2 OS: 5.9
CCNI2	FLJ16793	ENSG00000205089	Cyclin I family member 2	5	132747445-132754403	Predicted intracellular proteins	Evidence at transcript level	HPA056288	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Colorectal cancer:8.21e-4 (favourable)	Tissue enhanced	Mixed			duodenum: 3.8	Cell line enriched	6	MOLT-4: 21.8
CEACAM5	CD66e, CEA	ENSG00000105388	Carcinoembryonic antigen related cell adhesion molecule 5	19	41708585-41729798	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000021, CAB000022, HPA011041, HPA019758	Enhanced		Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		colon: 1012.7;rectum: 1086.0	appendix: 257.7	Cell line enriched	6	HaCaT: 11.8
CFTR	ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR	ENSG00000001626	Cystic fibrosis transmembrane conductance regulator	7	117465784-117715971	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001951, HPA021939	Enhanced				Liver cancer:9.44e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		gallbladder: 89.3	rectum: 49.0	Group enriched	19	CACO-2: 26.2;MOLT-4: 97.6;U-266/70: 47.9
CLDN2		ENSG00000165376	Claudin 2	X	106900164-106930861	Predicted membrane proteins	Evidence at protein level	CAB002609, HPA051548	Enhanced		Supported	Nucleoplasm<br>Cell Junctions	Thyroid cancer:1.70e-4 (favourable)	Group enriched	Tissue enhanced		gallbladder: 159.0;kidney: 171.8;seminal vesicle: 129.3	epididymis: 41.1	Group enriched	23	A549: 24.6;CACO-2: 18.2;RPTEC TERT1: 35.1
CXCL3	CINC-2b, GRO3, GROg, MIP-2b, SCYB3	ENSG00000163734	C-X-C motif chemokine ligand 3	4	74036589-74038807	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Cervical cancer:2.33e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 26.9;cervix, uterine: 33.6	appendix: 20.3	Cell line enhanced		BJ hTERT+: 39.2;hTEC/SVTERT24-B: 75.0;RPTEC TERT1: 32.7
CYP2W1	FLJ20359, MGC34287	ENSG00000073067	Cytochrome P450 family 2 subfamily W member 1	7	983199-989640	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012753	Uncertain				Urothelial cancer:5.85e-4 (unfavourable)	Group enriched	Tissue enhanced		adrenal gland: 5.5;duodenum: 6.2;skin: 9.7	placenta: 1.4	Group enriched	7	CACO-2: 11.2;Hep G2: 33.8
CYP4F12		ENSG00000186204	Cytochrome P450 family 4 subfamily F member 12	19	15672757-15697174	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058960	Approved				Cervical cancer:1.21e-4 (favourable), Urothelial cancer:2.33e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 36.2;small intestine: 42.3	skin: 22.3	Cell line enhanced		CAPAN-2: 14.8;HaCaT: 26.3;Karpas-707: 14.2;SiHa: 6.0
DMBT1	GP340, muclin, SALSA	ENSG00000187908	Deleted in malignant brain tumors 1	10	122560665-122643736	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA040778	Enhanced		Approved	Microtubule organizing center	Endometrial cancer:1.43e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 816.7;small intestine: 277.6	salivary gland: 136.1	Cell line enhanced		hTERT-HME1: 3.5;LHCN-M2: 7.8;RH-30: 20.9
DPEP1		ENSG00000015413	Dipeptidase 1 (renal)	16	89613308-89638456	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA009426, HPA012783	Enhanced		Approved	Nucleus<br>Cell Junctions	Renal cancer:6.84e-4 (favourable)	Tissue enriched	Tissue enhanced		kidney: 262.6;small intestine: 418.9	pancreas: 92.8	Cell line enhanced		Hep G2: 22.4;HHSteC: 11.8;U-937: 36.5
DUOXA2		ENSG00000140274	Dual oxidase maturation factor 2	15	45114321-45118421	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA063548	Enhanced					Group enriched	Tissue enhanced		gallbladder: 97.3;urinary bladder: 24.7	thyroid gland: 13.6	Cell line enhanced		U-2 OS: 1.0
EPHB2	DRT, EPHT3, ERK, Hek5, Tyro5	ENSG00000133216	EPH receptor B2	1	22710839-22921500	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013647, HPA071200	Approved		Supported	Nucleus<br>Plasma membrane	Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable)	Tissue enhanced	Mixed			rectum: 27.3	Cell line enhanced		HUVEC TERT2: 71.2;TIME: 69.5
FAM3D	EF7, OIT1	ENSG00000198643	Family with sequence similarity 3 member D	3	58633946-58666848	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013844	Approved				Head and neck cancer:1.89e-4 (favourable), Breast cancer:7.51e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 318.5;rectum: 484.7	salivary gland: 191.6	Not detected		
FFAR4	GPR120, GPR129, O3FAR1, PGR4	ENSG00000186188	Free fatty acid receptor 4	10	93566665-93604480	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA042563	Uncertain		Uncertain	Plasma membrane		Tissue enhanced	Tissue enhanced		colon: 8.4;rectum: 12.4	lung: 5.4	Cell line enhanced		A549: 1.2;HaCaT: 2.0;NB-4: 1.6
FLJ22763		ENSG00000241224	Uncharacterized LOC401081	3	109118252-109150514	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		duodenum: 97.6;small intestine: 94.5	kidney: 19.5	Cell line enhanced		CACO-2: 1.0
FRMD1	bA164L23.1, DKFZp434O0117, FLJ00181, FLJ22615, FLJ40260	ENSG00000153303	FERM domain containing 1	6	168055745-168081557	Predicted intracellular proteins	Evidence at protein level	HPA030347	Supported		Approved	Actin filaments		Tissue enriched	Tissue enhanced		colon: 5.8;stomach: 6.4;testis: 5.9	rectum: 4.6	Cell line enhanced		K-562: 2.8
FUT3	CD174, LE	ENSG00000171124	Fucosyltransferase 3 (Lewis blood group)	19	5842888-5851474	Blood group antigen proteins, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046966	Supported				Renal cancer:8.22e-7 (favourable), Breast cancer:6.86e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 68.0;esophagus: 83.0;small intestine: 63.1	rectum: 49.4	Group enriched	5	A-431: 40.5;RH-30: 14.4
GPR35		ENSG00000178623	G protein-coupled receptor 35	2	240605431-240631259	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level						Renal cancer:2.59e-5 (unfavourable), Lung cancer:5.86e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		duodenum: 41.4;small intestine: 42.3	colon: 18.4	Cell line enhanced		CACO-2: 17.1;CAPAN-2: 45.0;HDLM-2: 16.3;Hep G2: 22.7;HMC-1: 27.8
GRM8	GLUR8, GPRC1H, mGlu8, MGLUR8	ENSG00000179603	Glutamate metabotropic receptor 8	7	126438598-127253294	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA051481	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 4.1	testis: 3.0	Group enriched	6	HAP1: 3.1;HEK 293: 1.4;NTERA-2: 3.9;RH-30: 2.2;SCLC-21H: 4.1;SH-SY5Y: 2.0;U-2 OS: 1.3
HAND1	bHLHa27, eHand, Hxt, Thing1	ENSG00000113196	Heart and neural crest derivatives expressed 1	5	154474972-154478264	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA040925	Approved		Uncertain	Nucleus<br>Nuclear membrane		Group enriched	Tissue enhanced		smooth muscle: 16.8	adrenal gland: 6.2	Cell line enriched	8	SH-SY5Y: 123.7
HIST1H1B	H1.5, H1b, H1F5, H1s-3	ENSG00000184357	Histone cluster 1 H1 family member b	6	27866849-27867529	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012241, HPA055907	Approved		Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		bone marrow: 6.2;lymph node: 2.6	urinary bladder: 0.9	Cell line enhanced		MOLT-4: 8.9
HIST1H4L	H4.k, H4/k, H4FK	ENSG00000275126	Histone cluster 1 H4 family member l	6	27873199-27873510	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Tissue enhanced	Not detected			bone marrow: 0.3	Cell line enhanced		MOLT-4: 4.5;NB-4: 1.8;REH: 1.3
HOXB9	HOX2, HOX2E	ENSG00000170689	Homeobox B9	17	48621159-48626356	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031463			Approved	Nucleoplasm<br>Mitochondria	Head and neck cancer:6.64e-5 (unfavourable), Endometrial cancer:4.47e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		epididymis: 107.2	colon: 26.1	Cell line enhanced		HDLM-2: 315.3;HEK 293: 116.2;HMC-1: 112.5;K-562: 130.4
ITLN1	FLJ20022, hIntL, HL-1, ITLN, LFR	ENSG00000179914	Intelectin 1	1	160876539-160885170	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB012652, HPA063275, HPA067326	Enhanced					Tissue enhanced	Tissue enhanced		colon: 447.7;rectum: 1428.1;small intestine: 468.9	duodenum: 276.3	Cell line enhanced		HEL: 2.3;HL-60: 1.5;U-937: 5.7
KRT20	CK20, K20, MGC35423	ENSG00000171431	Keratin 20	17	40875941-40885227	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000032, HPA024309, HPA024684, HPA027236	Enhanced		Supported	Cytosol	Renal cancer:1.32e-4 (unfavourable), Liver cancer:7.05e-4 (unfavourable)	Group enriched	Tissue enhanced		colon: 356.1;duodenum: 252.4;rectum: 295.3;small intestine: 499.6	stomach: 82.3	Cell line enhanced		BEWO: 1.0;RT4: 2.3
KRT40	FLJ36600, KA36	ENSG00000204889	Keratin 40	17	40977716-40987135	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Not detected			lung: 0.2	Not detected		
LCN15	PRO6093, UNQ2541	ENSG00000177984	Lipocalin 15	9	136759634-136766255	Predicted secreted proteins	Evidence at protein level	HPA060584	Enhanced					Tissue enriched	Tissue enhanced		duodenum: 12.1;seminal vesicle: 5.0;small intestine: 4.0	colon: 2.8	Group enriched	14	Hep G2: 11.9;SCLC-21H: 3.0
LEFTY1	LEFTB, LEFTYB	ENSG00000243709	Left-right determination factor 1	1	225886282-225911382	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA047883, HPA056210	Approved				Renal cancer:2.48e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 58.4;pancreas: 20.4;rectum: 35.2	appendix: 9.6	Cell line enriched	7	NTERA-2: 50.6
LGALS4	GAL4	ENSG00000171747	Galectin 4	19	38801671-38813364	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025653, HPA031184, HPA031185, HPA031186	Enhanced		Uncertain	Plasma membrane	Renal cancer:2.28e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable)	Group enriched	Tissue enhanced		colon: 736.0;duodenum: 526.9;rectum: 640.3;small intestine: 493.5	gallbladder: 138.8	Cell line enhanced		CACO-2: 1.0;RT4: 2.2;SH-SY5Y: 1.0
LGR5	FEX, GPR49, GPR67, HG38	ENSG00000139292	Leucine rich repeat containing G protein-coupled receptor 5	12	71439770-71586310	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA012530	Approved				Lung cancer:5.09e-4 (favourable)	Group enriched	Tissue enhanced		fallopian tube: 26.6;placenta: 26.9	seminal vesicle: 9.8	Group enriched	6	Hep G2: 25.0;SH-SY5Y: 110.2
LINC00675		ENSG00000263429	Long intergenic non-protein coding RNA 675	17	10794913-10804099	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		colon: 36.9;rectum: 40.8;stomach: 44.3	duodenum,small intestine: 18.3	Cell line enriched	8	RT4: 3.2
LY6G6D	C6orf23, G6D, Ly6-D, MEGT1, NG25	ENSG00000244355	Lymphocyte antigen 6 family member G6D	6	31715356-31717804	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054412	Uncertain					Tissue enriched	Tissue enhanced		seminal vesicle: 2.0	prostate: 0.8	Cell line enhanced		HEL: 1.6
MAB21L2		ENSG00000181541	Mab-21 like 2	4	150581922-150584693	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049324, HPA059864			Enhanced	Nucleus<br>Cytosol		Tissue enhanced	Tissue enhanced		colon: 18.3;smooth muscle: 26.2	small intestine: 12.4	Group enriched	20	HHSteC: 4.9;SH-SY5Y: 16.0
MYO7B		ENSG00000169994	Myosin VIIB	2	127535802-127637729	Predicted intracellular proteins	Evidence at protein level	HPA039131	Enhanced				Renal cancer:1.25e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 113.9;small intestine: 92.1	colon: 35.2	Cell line enriched	17	MOLT-4: 228.8
NKD1		ENSG00000140807	Naked cuticle homolog 1	16	50548330-50649249	Predicted intracellular proteins	Evidence at protein level	HPA041352, HPA049413	Uncertain		Approved	Nucleoli fibrillar center		Tissue enhanced	Mixed			smooth muscle: 8.1	Group enriched	6	AF22: 6.2;CACO-2: 11.1;Hep G2: 24.6
NMUR2	NMU2R	ENSG00000132911	Neuromedin U receptor 2	5	152391532-152433368	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA045836	Enhanced					Group enriched	Tissue enhanced		stomach: 1.1;testis: 2.2	thyroid gland: 0.9	Cell line enriched	10	EFO-21: 8.9
NXPE2	FAM55B, FLJ25224	ENSG00000204361	Neurexophilin and PC-esterase domain family member 2	11	114678386-114706933	Predicted intracellular proteins	Evidence at protein level	HPA039744, HPA039876	Enhanced				Colorectal cancer:9.29e-5 (favourable)	Tissue enhanced	Tissue enhanced		colon: 9.5;epididymis: 30.3;rectum: 9.7	salivary gland: 8.2	Not detected		
OLFM4	GC1, GW112, OlfD	ENSG00000102837	Olfactomedin 4	13	53028759-53052057	Predicted secreted proteins	Evidence at protein level	HPA077718	Enhanced				Breast cancer:8.77e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 1193.9;rectum: 611.5;small intestine: 1437.8	colon: 445.0	Cell line enhanced		BEWO: 5.1;BJ hTERT+: 15.0;HaCaT: 22.9
PIGR		ENSG00000162896	Polymeric immunoglobulin receptor	1	206928518-206946466	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA006154, CAB009454, HPA012012	Enhanced				Breast cancer:1.22e-5 (favourable), Renal cancer:5.08e-5 (favourable), Endometrial cancer:2.57e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 1688.0;duodenum: 2659.3	rectum: 1335.9	Cell line enriched	7	EFO-21: 33.8
PLCB4		ENSG00000101333	Phospholipase C beta 4	20	9068763-9481242	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007951	Supported		Approved	Nucleoplasm<br>Microtubules	Endometrial cancer:2.11e-4 (favourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 58.5	epididymis: 30.5	Cell line enhanced		fHDF/TERT166: 87.3;LHCN-M2: 74.5;RPTEC TERT1: 85.5
POF1B	FLJ22792, POF	ENSG00000124429	Premature ovarian failure, 1B	X	85277396-85379743	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002033, HPA050027	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:2.03e-4 (unfavourable), Endometrial cancer:3.08e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		skin: 144.4	rectum: 52.8	Cell line enhanced		A549: 19.6;CAPAN-2: 19.5;HaCaT: 19.9;RT4: 60.9
POU5F1B	OTF3C, OTF3P1, POU5F1P1	ENSG00000212993	POU class 5 homeobox 1B	8	127414290-127420069	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058267			Supported	Nucleoplasm		Tissue enhanced	Not detected			parathyroid gland: 0.7	Cell line enhanced		hTERT-HME1: 1.1
PPBP	b-TG1, Beta-TG, CTAP3, CTAPIII, CXCL7, LA-PF4, LDGF, MDGF, NAP-2, NAP-2-L1, PBP, SCYB7, TGB, TGB1, THBGB1	ENSG00000163736	Pro-platelet basic protein	4	73987038-73988197	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008354, CAB017624	Supported				Cervical cancer:6.17e-4 (unfavourable)	Tissue enriched	Tissue enhanced		bone marrow: 110.6	spleen: 24.3	Cell line enhanced		HBEC3-KT: 1.6;HEL: 6.2;RPTEC TERT1: 1.1
PTPRO	GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2	ENSG00000151490	Protein tyrosine phosphatase, receptor type O	12	15322397-15597399	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA034525	Enhanced					Tissue enhanced	Tissue enhanced		rectum: 33.0	cerebral cortex: 21.7	Cell line enhanced		NTERA-2: 6.6;SCLC-21H: 4.7;SH-SY5Y: 8.4
R3HDML	dJ881L22.3	ENSG00000101074	R3H domain containing like	20	44336986-44351235	Predicted secreted proteins	Evidence at protein level	HPA070264	Enhanced					Tissue enhanced	Tissue enhanced		duodenum: 2.2;small intestine: 2.7	testis: 0.8	Not detected		
RETNLB	FIZZ2, HXCP2, RELMb	ENSG00000163515	Resistin like beta	3	108743424-108757384	Predicted secreted proteins	Evidence at transcript level	HPA049152	Approved				Colorectal cancer:6.86e-5 (favourable)	Tissue enriched	Tissue enhanced		colon: 73.5;rectum: 270.7	small intestine: 36.9	Not detected		
RNF186	FLJ20225	ENSG00000178828	Ring finger protein 186	1	19814029-19815278	Predicted membrane proteins	Evidence at protein level	HPA034547, HPA035558	Enhanced					Tissue enhanced	Tissue enhanced		duodenum: 132.4;epididymis: 82.2;small intestine: 46.5	kidney: 26.2	Cell line enhanced		RPMI-8226: 1.2
RNF43	DKFZp781H0392, FLJ20315, URCC	ENSG00000108375	Ring finger protein 43	17	58352500-58417595	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA008079	Uncertain				Renal cancer:6.04e-9 (favourable)	Tissue enhanced	Mixed			duodenum: 23.4	Cell line enhanced		CACO-2: 20.6;Hep G2: 33.5
RUBCNL	C13orf18, FLJ21562, KIAA0226L	ENSG00000102445	RUN and cysteine rich domain containing beclin 1 interacting protein like	13	46342000-46438190	Predicted intracellular proteins	Evidence at protein level	HPA026614	Approved		Supported	Cytosol	Endometrial cancer:3.76e-5 (favourable)	Tissue enriched	Mixed			lymph node: 35.0	Cell line enhanced		Daudi: 99.1;REH: 36.6;U-698: 157.0
RXFP4	GPCR142, GPR100, RLN3R2, RXFPR4	ENSG00000173080	Relaxin/insulin like family peptide receptor 4	1	155941710-155942949	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		colon: 2.0;duodenum: 1.4;rectum: 2.2	small intestine: 1.1	Not detected		
SGK2		ENSG00000101049	SGK2, serine/threonine kinase 2	20	43558968-43588237	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008859, HPA011387	Uncertain		Supported	Nucleoplasm	Urothelial cancer:5.65e-4 (favourable)	Group enriched	Mixed			kidney: 43.2	Group enriched	5	A549: 16.2;CAPAN-2: 12.2;EFO-21: 6.5;Hep G2: 12.5;RPTEC TERT1: 19.0
SLC26A3	CLD, DRA	ENSG00000091138	Solute carrier family 26 member 3	7	107765467-107803225	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036055	Approved					Tissue enriched	Tissue enhanced		colon: 1075.0;duodenum: 577.9;rectum: 961.7	seminal vesicle: 185.8	Cell line enhanced		RPMI-8226: 1.9
SLC35D3	FRCL1	ENSG00000182747	Solute carrier family 35 member D3	6	136922264-136925639	Predicted membrane proteins, Transporters	Evidence at protein level	HPA030431, HPA067497	Uncertain		Approved	Microtubule organizing center		Tissue enhanced	Tissue enhanced		adrenal gland: 1.2	lung,stomach: 0.6	Group enriched	16	SCLC-21H: 4.2;SH-SY5Y: 16.3
SLC6A7	PROT	ENSG00000011083	Solute carrier family 6 member 7	5	150189957-150222788	Predicted membrane proteins, Transporters	Evidence at protein level	HPA028907	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 16.9;rectum: 4.2	colon: 2.9	Not detected		
TDGF1	CR, CRIPTO, Cripto-1	ENSG00000241186	Teratocarcinoma-derived growth factor 1	3	46574534-46582463	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enhanced		spleen: 24.8	kidney: 8.1	Group enriched	30	HEL: 19.6;NTERA-2: 95.4
TLDC2	C20orf118, dJ132F21.2	ENSG00000101342	TBC/LysM-associated domain containing 2	20	36876121-36894235	Predicted intracellular proteins	Evidence at transcript level	HPA047468	Approved				Renal cancer:9.97e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		duodenum: 19.0;small intestine: 20.1	rectum: 13.3	Cell line enriched	10	HMC-1: 30.5
TMEM150B	TMEM224, TTN2	ENSG00000180061	Transmembrane protein 150B	19	55312801-55334048	Predicted membrane proteins	Evidence at transcript level						Renal cancer:6.14e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		duodenum: 69.8;small intestine: 66.5	lung: 18.9	Cell line enhanced		CACO-2: 7.6;HMC-1: 4.0;U-937: 16.3
TMEM211	bA9F11.1	ENSG00000206069	Transmembrane protein 211	22	24934954-24946695	Predicted membrane proteins	Evidence at transcript level	HPA066784	Uncertain					Tissue enhanced	Tissue enhanced		cervix, uterine: 3.7;stomach: 2.7	salivary gland: 1.4	Not detected		
TPSG1	PRSS31, TMT	ENSG00000116176	Tryptase gamma 1	16	1221651-1225257	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA060458	Enhanced				Renal cancer:1.76e-8 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 14.6;duodenum: 14.3;rectum: 9.5;small intestine: 10.5	ovary: 2.5	Group enriched	8	HMC-1: 20.4;MCF7: 6.0
TRABD2A	C2orf89, TIKI1	ENSG00000186854	TraB domain containing 2A	2	84821650-84907008	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045817	Approved					Group enriched	Tissue enhanced		colon: 35.4;ovary: 30.7;rectum: 43.1	lymph node: 11.7	Cell line enhanced		BEWO: 38.1;HDLM-2: 29.0;hTEC/SVTERT24-B: 17.5;SiHa: 18.3
TRIM15	RNF93, ZNF178, ZNFB7	ENSG00000204610	Tripartite motif containing 15	6	30163206-30172696	Predicted intracellular proteins	Evidence at protein level	HPA047527	Uncertain					Tissue enhanced	Tissue enhanced		colon: 2.6;duodenum: 3.6	appendix,small intestine: 1.1	Cell line enriched	24	HEL: 15.2
TRIM40	RNF35	ENSG00000204614	Tripartite motif containing 40	6	30136108-30148735	Predicted intracellular proteins	Evidence at protein level	HPA043818	Uncertain					Tissue enhanced	Not detected			colon: 0.4	Cell line enriched	11	HEL: 1.0
TSPAN8	CO-029, TM4SF3	ENSG00000127324	Tetraspanin 8	12	71125085-71441898	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	CAB026009, HPA044337	Enhanced		Approved	Nucleoplasm	Urothelial cancer:7.36e-5 (favourable), Renal cancer:9.66e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 910.6;duodenum: 905.9;rectum: 911.5;small intestine: 909.2	stomach: 573.4	Cell line enhanced		CACO-2: 36.0;HeLa: 34.8;PC-3: 151.7;RT4: 30.6
TUBAL3	FLJ21665	ENSG00000178462	Tubulin alpha like 3	10	5393098-5404830	Predicted intracellular proteins	Evidence at protein level	HPA045900, HPA063394	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 24.4;small intestine: 31.0	colon: 11.8	Group enriched	6	HEL: 11.9;K-562: 3.8
UGT2B17		ENSG00000197888	UDP glucuronosyltransferase family 2 member B17	4	68537184-68568527	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045108	Supported					Group enriched	Tissue enhanced		colon: 372.4;duodenum: 371.2;small intestine: 522.5	rectum: 151.7	Cell line enhanced		RPMI-8226: 1.2
USH1C	AIE-75, DFNB18, harmonin, NY-CO-37, NY-CO-38, PDZ-73, PDZ73, PDZD7C	ENSG00000006611	USH1 protein network component harmonin	11	17493895-17544416	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB013690, HPA027398, HPA027492, HPA028033	Supported		Enhanced	Cytosol	Liver cancer:2.20e-4 (unfavourable), Renal cancer:9.41e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 99.2;small intestine: 106.9	kidney: 55.4	Cell line enhanced		CACO-2: 50.5;CAPAN-2: 7.4;HeLa: 14.4
XXbac-BPG32J3.19		ENSG00000250641		6	31706904-31717918	Predicted membrane proteins	No evidence	HPA008053	Uncertain					Tissue enriched	Not detected			testis: 0.5	Not detected		
